Identification of Neuregulin 1 as Predictor Outcome in Intracranial Astrocytoma

Ridha Dharmajaya*, Abdurrahman Mouza*

Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Abstract

BACKGROUND: Astrocytoma is the most common primary brain tumor. The combination of adhesion molecules, proteases, and cytokines that regulate their expression likely underlies tumor progression. The cytokine of neuregulin 1 (NRG1) has a role in progression and invasion of tumor cells by activating signal after binding its receptor.

AIM: To identification NRG1 expression with characteristic of intracranial astrocytoma patient is the purpose of this study.

METHODS: This study uses analytic method with retrospective study. It analyzed the association between NRG1 expressions in astrocytoma patients. The study included 32 samples which were admitted to Haji Adam Malik Hospital Medan from September 2016 to August 2018.

RESULTS: There was no significant association between NRG1 expression with age (p = 0.853) and gender (p = 0.565) of astrocytoma patients, while there was a significant association between NRG1 expression with cell proliferation (p = 0.00), WHO grading of astrocytoma (p = 0.00), and outcomes (p = 0.023). According to this study, the most common results are strong NRG1 expression has many cells proliferation in 10 (31.1%) patients, strong NRG1 expression with Grade IV astrocytoma found in 7 (21.9%) patients, and moderate NRG1 expression in live patient found in 7 (21.9%) patient.

CONCLUSION: There is significant association between NRG1 expression and cell proliferation, WHO grading of astrocytoma, and outcomes.

Introduction

Astrocytoma is the most common primary brain tumor. In the United States, incidence of astrocytoma is 6.5 per 100,000 population, whereas mortality rate are 12,760 cases. Annually, new cases of high-grade astrocytoma are 11,000 cases [1]. Astrocytoma is a tumor from glial cell, called astrocyte. The World Health Organization classifies astrocytoma using four grades according to the growth rate and metastasis [2]. Astrocytoma is usually found in male and adult patient [3].

Astrocytoma is one of brain tumors that can have metastases. The metastasis is facilitated by proliferation and migration of cell tumor. A complex interplay among adhesion molecules, proteases, and cytokines that regulate their expression likely underlies tumor progression and invasion [4]. Cytokine that affected the growth of cell tumor was known for long time. Among cytokines, NRG1 plays the most important role in growing and migration of cell tumor. Complex interplay between NRG1 and receptor activate intracellular biology process adding to tumorigenesis [5].

Neuregulin 1 expression is considered as a prognostic parameter of an astrocytoma. In low-grade astrocytoma, age is one of significant risk factors in predicting outcome [6].

Complex interplay between NRG1 and ErbB receptor affects mouse brain glial cell changed to be malignant astrocytoma. This binding induces differentiation and proliferation of mouse astrocyte cell. Zhao in 2013 indicated that L1, a transmembrane adhesion molecule of the immunoglobulin superfamily, plays important roles in tumor progression and metastatic behavior [7].

The trigger of the growth and migration of tumor is suspected by overexpression of the NRG1 and ErbB signal. Inhibition of NRG1 signaling inhibited primary tumor growth and enhanced the magnitude and duration of the respond to chemotherapy [8].

The purpose of this study was to analyze the expression of NRG1 on human astrocytoma. The relationship of NRG1 and characteristic of patient of intracranial astrocytoma is observed. The role of NRG1 in astrocytoma prognosis in the Indonesian population is not clear. Therefore, the researcher
is interested to study the relationship of NRG1 and characteristic of patient of intracranial astrocytoma patients.

**Methods**

*Inclusion criteria for patients*

Patients were diagnosed with intracranial astrocytoma by clinical and radiological parameters. Patients were operated by tumor removal. The definitive diagnose was confirmed by anatomy pathology study.

*Exclusion criteria for patients*

Patients have comorbid diseases such as diabetes mellitus, renal, and liver dysfunctions. Patients have recurrence and recidive of astrocytoma. There are other tumors, such as breast cancer, cardiac cancer, ovarian cancer, and prostate cancer. All patients and controls gave informed consent, and the study protocol was approved by the Institutional Ethics Committee.

**Study design**

The study analyzes relationship of NRG1 and the characteristic of patient of intracranial astrocytoma who were admitted in Adam Malik Hospital, Medan. This study is a retrospective study that is using an analytic method. The study included 32 samples. The sampling technique of this study is total sampling. The study was undertaken at Adam Malik Hospital, Medan since September 2016–August 2018.

*Technique of sample collection*

All paraffin specimen of astrocytoma and data of the patients from September 2016 to August 2018 were collected from medical record and data of neurosurgery department assessment.

The data included gender, age, the WHO histopathology grading of astrocytoma, cell proliferation, outcome, and NRG1 expression. The cell proliferation and NRG1 immunohistochemistry tests are performed in all paraffin specimens.

Cell proliferation interpretation is recorded as followed: mild group as <4 mitotes per 10 High Power Field (HPF), moderate group as 4–19 mitoses per 10 HPF, and high group as >20 mitoses per 10 HPF. Interpretation of intensity (0, 1+, 2+, and 3+) and percentage of immunoreactive cells of neuregulin 1 staining were recorded as followed: 3+, strong staining intensity in 50% cells; 2+, moderate staining intensity in 50% cells; 1+, faint or weak staining intensity in 50% cells; and 0, no or equivocal staining in tumor cells or 50% of cells staining at any given intensity, which were defined as NRG1-negatif[9].

Figure 1: Cell proliferation. (a) Cell Proliferation: mild, (b) Cell Proliferation: moderate, (c) Cell Proliferation: high

Four micron-thick section of tumor slide is placed in positive charged slides Optiplus and heated at 60°C for 30 min. Deparaffinization slide uses xylene as 2 times for 5 min and rehydrated by ethanol. Endogenous peroxidase activity is blocked with incubation at 100 μ H₂O₂ 3% and methanol at humid room for 5 min. The slide is rehydrated by phosphate buffered saline (PBS). Antigen is got by giving buffer citrate (pH 6.0) then cooled by RT for 20–30 min. The slide is blocked with goat serum 1:20 (BioGenex San Ramon, CA) for 20 min. The slide is incubated with monoclonal antibody NRG1 overnight in 4°C, then it is washed with PBS and incubated 100 μ streptavidin-horseradish peroxidase conjugate (Dako Corporation, EA 93013, USA) for 30 min. The antibody is dripped by substrate 3,3’-diaminobenzidine for 10 min. The slide is colored by hematocyline Mayer’s for 30 min, washed and rehydrated with ethanol, cleared with xylene, mount with mounting medium.

**Statistical analysis**

Statistical analysis was performed using Statistica software, ver 7.1. Due to the distribution which was not normal (according to Kolmogorov–Smirnov test), the variable differences were tested using non-parametric tests (Wilcoxon Matched Pair Test or Friedman ANOVA test – Chi-square). The correlation between parameters was analyzed using the Pearson correlation coefficient. Significance was set up at p < 0.05.

**Results**

Data are preceded by software. Categoric variable is presented in frequency and percentage. Demography and medic data that include...
name, age, the WHO histopathology grading of astrocytoma, cell proliferation, outcome, and NRG1 expression are analyzed by computerize using Spearman test. $p \leq 0.05$ means that there is significant relationship, otherwise $p$ value $>0.05$ means that there is not significant relationship NRG1 expression and age.

The study demonstrated that the most NRG1 expression is weak expression in adult as many 8 (25%) samples, while the least NRG1 expression is negative expression and weak expression in children as many 2 (6.3%) samples, respectively. After analyzing with Spearman test, there is not significant relationship between NRG1 expression and age ($p = 0.853$), Table 1.

**Table 1: NRG1 expression and age**

| Category   | Children n (%) | Adult n (%) | Elderly n (%) | $p$    |
|------------|----------------|-------------|---------------|--------|
| None       | 2 (6.3)        | 3 (9.4)     | 0 (0)         | 0.853  |
| Weak       | 2 (6.3)        | 8 (25)      | 0 (0)         |        |
| Moderate   | 3 (9.4)        | 5 (15.6)    | 0 (0)         |        |
| Strong     | 3 (9.4)        | 6 (18.8)    | 0 (0)         |        |

**NRG1 expression and genre**

Weak NRG1 expression in male and strong NRG1 expression in male is the most finding NRG1 expression in this study, as many 6 (18.8%) samples, respectively; otherwise, negative NRG1 expression in male is the least finding NRG1 expression in this study, as many 2 (6.3%) samples. After analyzing with Spearman test, there is not significant relationship between NRG1 expression and genre ($p = 0.565$), (Table 2).

**Table 2: NRG1 expression and genre**

| Category   | Male n (%) | Female n (%) |
|------------|------------|--------------|
| None       | 2 (6.3)    | 3 (9.4)      |
| Weak       | 6 (18.8)   | 4 (12.5)     |
| Moderate   | 3 (9.4)    | 5 (15.6)     |
| Strong     | 6 (18.8)   | 3 (9.4)      |

**NRG1 expression and cell proliferation**

The strong NRG1 expression with high cell proliferation is the most finding NRG1 expression, as many 10 (31.1%) samples, while the moderate NRG1 expression with high cell proliferation is the least finding NRG1 expression. After analyzing with Spearman test, there is significant relationship between NRG1 expression and cell proliferation ($r = 0.906$, $p = 0.00$), (Table 3).

**Table 3: NRG1 expression and cell proliferation**

| Category   | Mild n (%) | Moderate n (%) | High n (%) | $r$ (p) |
|------------|------------|---------------|-----------|---------|
| None       | 5 (15.6)   | 0             | 0         | 0.906   |
| Weak       | 2 (6.3)    | 8 (25)        | 0         | (0.00)  |
| Moderate   | 0          | 7 (21.9)      | 1 (3.1)   |         |
| Strong     | 0          | 0             | 10 (31.1) |         |

**NRG1 expression and the WHO histopathology grading of astrocytoma**

The strong NRG1 expression in fourth grade of astrocytoma is the most finding, as many 7 (21.9%) samples. Otherwise, the negative NRG1 expression in second grade of astrocytoma is the least finding, as many 1 (3.1%) sample. After analyzing with Spearman test, there is significant relationship between NRG1 expression and the WHO histopathology grading of astrocytoma ($r = 0.88$, $p = 0.00$), (Table 4).

**Table 4: NRG1 expression and the WHO histopathology grading of astrocytoma**

| Category   | Grade I n (%) | Grade II n (%) | Grade III n (%) | Grade IV n (%) | $r$ (p) |
|------------|---------------|----------------|-----------------|---------------|---------|
| None       | 4 (12.5)      | 1 (3.1)        | 0               | 0             | 0.88 (0.00) |
| Weak       | 6 (18.8)      | 4 (12.5)       | 0               | 0             |         |
| Moderate   | 0             | 5 (15.6)       | 3 (9.4)         | 0             |         |
| Strong     | 0             | 0              | 5 (15.6)        | 7 (21.9)      |         |

**NRG1 expression and outcome**

Moderate NRG1 expression in live patient post tumor removal is the most findings, as many
This study demonstrated that there is significant relationship between NRG1 expression and outcome \((r = 0.514, p = 0.03)\). This result is compatible to Anvari statement that the WHO grading of astrocytoma has relationship with mortality \([16]\). Ten survival rates of astrocytoma patients in Grade II astrocytoma are 35\%. The central nervous system cancer is the main cause of death of solid tumor in children and the third cause of death in adolescent and adult, especially at age 15–34 years old \([1]\).

### Limitations of study

The sample size was too small to allow for a generalization of the results.

### Conclusions

There was significant association between NRG1 expression and cell proliferation, the WHO grading of astrocytoma and outcomes.

### Authors’ Contributions

Conception of the work: RD, AM; Design of the work: RD, AM; Acquisition/analysis/interpretation of the data: RD and AM. RD and AM have read and approved the final version of manuscript.

### Acknowledgments

The authors would like to thank Universitas Sumatera Utara and the Department of Pathology Anatomy at Universitas Sumatera Utara, Indonesia.

### Ethics Approval and Consent to Participate

Ethical approval by HEALTH RESEARCH ETHICAL COMMITTEE medical faculty of Universitas Sumatera Utara / Haji Adam Malik General Hospital. Consent to participate is not applicable for retrospective analysis.
Availability of Data and Materials

The datasets analyzed during current study are available from the corresponding author upon request.

References

1. Winn HR. Low-grade glioma. In: Youmans and Winn Neurological Surgery. 7th ed. New York: Elsevier; 2017. p. 4396.
2. National Organization for Rare Disorders, Astrocytoma; 2015. Available from: https://www.rarediseases.org/rare-diseases/astrocytoma. [Last accessed on 2018 Aug 27].
3. American Brain Tumor Association, Glioblastoma and Malignant Astrocytoma; 2017.
4. Zhao W, Schachner M. Neureguline-1 enhances cell adhesion molecule L1 expression in human glioma cells and promotes their migration as a function of malignancy. J Neuropathol Exp Neurol. 2013;72(3):244-55. https://doi.org/10.1097/nen.0b013e3182863dc5 PMid:23399902
5. Maiti AK, Ghosh K, Chatterjee U, Chakrobarti S, Chatterjee S. Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytoma. Neurol India. 2008;56(4):456-62. https://doi.org/10.4103/0028-3886.44827 PMid:19127042
6. Forsyth PA, Swah EG, Scheithauer BW, O’Fallon JR, Layton DD, Katzmann JA. Supratentorial pilocytic astrocytoma. Cancer. 1993;72:1335-42.
7. Ritch PS, Carroll SL, Sontheimer H. Neuregulin 1 Enhances Motility and Migration of Astrocytic Glioma Cell. Alabama: National Institutes of Health Public Access; 2003. https://doi.org/10.1074/jbc.m213074200 PMid:21620900
8. Liu Y, Ford BD, Mann MA, Fischbach GD. Neuregulin-1 increases the proliferation of neuronal progenitors from embryonic neural stem cells. Dev Biol. 2005;283(2):437-45. https://doi.org/10.1016/j.ydbio.2005.04.038 PMid:15949792
9. Pan B, Wang R, Huang Y, Garfield D, Chen H. HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma. Onco Targets Ther. 2015;8:1185-91. https://doi.org/10.2147/ott.s78116 PMid:26045672
10. Douet V, Chang L, Pritchett A, Lee K, Keating B, Bartsch H, et al. Schizophrenia-risk variant rs6994992 in the neuregulin-1 gene on brain developmental trajectories in typically developing children. Transl Psychiatry. 2014;4(5):e392. https://doi.org/10.1038/tp.2014.41 PMid:24865593
11. Anvari K, Seilian Toussi M, Shahidseales S, Motlagh F, Reza Ehsaeem A, Afshari F. Treatment outcomes and prognostic factors in adult astrocytoma: In North East of Iran. Iran J Cancer Prev. 2016;9(4):e4099. https://doi.org/10.17795/ijcp-4099 PMid:27822343
12. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: An analysis of histologic parameters. Am J Surg Pathol. 1997;21(12):1455-65. https://doi.org/10.1097/00000478-199712000-00008 PMid:9414189
13. Prevot V, Rio C, Cho GJ, Lomniczi A, Heger S, Neville CM, et al. Normal female sexual development requires neuregulin-erbB receptor signaling in hypothalamic astrocytes. J Neurosci. 2003;23(1):230-9. https://doi.org/10.1523/jneurosci.23-01-00230.2003 PMid:12514220
14. Taylor SB, Markham JA, Taylor AR, Kanaskie BZ, Koenig JI. Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II neuregulin 1 rats. Behav Brain Res. 2011;224(2):223-32. https://doi.org/10.1016/j.bbr.2011.05.008 PMid:21620900
15. Ritch PA, Carroll SL, Sontheimer H. Neuregulin 1 Enhances Motility and Migration of Astrocytic Glia Cell. Alabama: National Institutes of Health Public Access; 2003. https://doi.org/10.1074/jbc.m213074200
16. Wadugu B, Kuhn B. The role of neuregulin/ErbB2/Erbb4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol. 2012;302(11):H2139-47. https://doi.org/10.1152/ajpheart.00063.2012 PMid:22427524